Torsades de pointes (TdP) is a ventricular tachycardia associated with prolongation of the corrected QT (QTc) interval, and which may be caused by > 150 widely used drugs. TdP results in catastrophic outcomes, including sudden cardiac death. Older age is a risk factor for drug-induced TdP, possibly due to declining serum progesterone and testosterone concentrations in postmenopausal women and men, respectively. The ECG biomarkers J-Tpeak and Tpeak-Tend, represent early and late repolarization, respectively, as well as dispersion of repolarization (Tpeak-Tend). Preclinical evidence and preliminary data from our group indicate that progesterone and testosterone exert protective effects against drug-induced prolongation of ventricular repolarization. Effective means of reducing the risk of drug-induced QTc interval prolongation and TdP in high risk populations requiring therapy with QTc-prolonging drugs have not been identified, and the effects of sex hormones on early vs late ventricular repolarization and dispersion of repolarization are unknown. The objectives of this research are to evaluate novel therapeutic approaches to attenuate drug-induced QTc lengthening. Our central hypothesis is that drug-induced QTc lengthening is attenuated by administration of oral progesterone and transdermal testosterone.
Specific Aim 1 : Determine the efficacy of oral progesterone as a preventive method to attenuate drug-induced QTc interval lengthening in postmenopausal women.
Specific Aim 2 : Determine the influence of oral progesterone on drug-induced lengthening of early and late ventricular repolarization in postmenopausal women.
Specific Aim 3 : Determine the efficacy of transdermal testosterone as a preventive method to attenuate drug-induced QTc interval lengthening in men ? 65 years of age.
Specific Aim 4 : Determine the influence of transdermal testosterone on drug-induced lengthening of early and late ventricular repolarization in men ? 65 years of age.
Specific Aims 1 &2 will be achieved via a prospective, randomized, double-blind, placebo-controlled two-way crossover study in postmenopausal women age ? 50 years (n=48). Each subject will take oral progesterone 400 mg or matching placebo daily for 7 days (? 14-day washout period between phases). On day 7, each subject will receive a single dose of the QTc-lengthening drug ibutilide 0.003 mg/kg.
Specific Aims 3 &4 will be achieved via a prospective, randomized, double-blind, placebo-controlled two-way crossover study in men ? 65 years of age (n=35). Each subject will apply transdermal testosterone 1% 100 mg or transdermal placebo once daily for 3 days (? 7-day washout period between phases). On day 7, each subject will ibutilide 0.003 mg/kg. In both studies, post-ibutilide QT, J-Tpeak and Tpeak-Tend intervals and serum ibutilide concentrations will be determined serially. Primary outcome measures: 1) Maximum post-ibutilide QTc intervals, 2) Maximum post-ibutilide % change in QTc intervals, 3) Area under the QTc interval-time curves, and 4) J-Tpeak and Tpeak-Tend intervals. This research will identify effective approaches for reducing the risk of drug-induced QTc interval prolongation in high-risk patients.
Drug-induced torsades de pointes (TdP) is an irregular heartbeat that results in catastrophic outcomes, including sudden cardiac death. Older patients are at greater risk for drug-induced TdP, due to declining blood levels of progesterone (postmenopausal women) and testosterone (older men). This research will determine if administration of progesterone (to postmenopausal women) or testosterone (to older men) diminishes drug- induced lengthening of an EKG measurement known as the QT interval, which is associated with TdP risk, and will be the first to identify an effective therapy for reducing the risk of this irregular heartbeat in high risk patients.
